Diabetes Clinical Trials | A Drug Pipeline Analysis Report 2022 … – Digital Journal

United States, Nevada, Las Vegas, DelveInsight’s ‘Diabetes Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline Diabetes therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetes pipeline domain.
Key Takeaways from the Diabetes Pipeline Report
Diabetes Overview
Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or alternatively, when the body cannot effectively use the insulin it produces. The vast majority of Diabetes can be classified as either type 1 or type 2 diabetes. Type 1 diabetes is an autoimmune disease is characterized by a lack of insulin production by the pancreas. Type 2 diabetes occurs when body becomes resistant to insulin, and sugar builds up in the blood. About 90% of people with diabetes around the world have type 2. It is largely the result of excess body weight and physical inactivity. Diabetes can cause a heart attack, stroke, blindness, kidney disease, nerve damage, and other serious health problems.
Diabetes Pipeline Analysis: Drug Profile
Enavogliflozin – Daewoong
Enavogliflozin (DWP 16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. The molecule is in phase-3 clinical trials for type-2 diabetic treatment. Enavogliflozin demonstrates the lowering of blood sugar and safety in diabetic patients in phase 2 clinical trials.
Discover more about the emerging Diabetes drugs @ Diabetes Treatment Drugs
Diabetes Key Companies
Diabetes Pipeline Therapies
Diabetes Pipeline Therapeutics Assessment
Scope of the Diabetes Pipeline Report 
Find out more about the Diabetes treatment options in development @ Diabetes Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase  II)
7. Early Stage Products (Phase  I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Request for a sample report to know more about the leading companies in the diabetes pipeline domain.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

source